mk-5890
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2018 (NCT03396445)
Timeline
Indications
Mechanism of action
- CD27 antigenINHIBITOR
CD27 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095364 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06829199 | Phase 2 | Mar 26, 2025 | Merck |
| NCT04924101 | Phase 2 | Jul 15, 2021 | Merck |
| NCT04165096 | Phase 2 | Jan 17, 2020 | Merck |
| NCT03396445 | Phase 1 | Feb 18, 2018 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1